Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort
Open Access
- 16 April 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 375 (9722), 1278-1286
- https://doi.org/10.1016/s0140-6736(10)60057-8
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialThe Lancet, 2010
- Tuberculosis and Trimethoprim-SulfamethoxazoleAntimicrobial Agents and Chemotherapy, 2009
- Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral‐Treated HIV InfectionThe Journal of Infectious Diseases, 2009
- Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trialBMJ, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: Findings from the first year of the CIPRA-SA cohortCytometry Part B: Clinical Cytometry, 2008
- Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/μlAIDS, 2008
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006
- Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in ZambiaJAMA, 2006
- Co-trimoxazole for childhood febrile illness in malaria-endemic regionsThe Lancet, 1991